Three Times Daily Dosing of UT-15C

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the pharmacokinetics of three-times daily dosing of UT-15C in healthy volunteers

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: United Therapeutics
• Treatments: Treprostinil

Criteria

• Healthy male and female subjects

• aged 18-55 years of age;

• weight between 50 and 100 kg, with a body mass index (BMI) between 19.0 and 29.9 kg/m2, inclusive for female subjects and

• weight between 50 and 120 kg, with a BMI between 19.0 and 32.0 kg/m², inclusive for male subjects.